Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock


      Our goal was to determine the impact of the initiation of inappropriate antimicrobial therapy on survival to hospital discharge of patients with septic shock.


      The appropriateness of initial antimicrobial therapy, the clinical infection site, and relevant pathogens were retrospectively determined for 5,715 patients with septic shock in three countries.


      Therapy with appropriate antimicrobial agents was initiated in 80.1% of cases. Overall, the survival rate was 43.7%. There were marked differences in the distribution of comorbidities, clinical infections, and pathogens in patients who received appropriate and inappropriate initial antimicrobial therapy (p < 0.0001 for each). The survival rates after appropriate and inappropriate initial therapy were 52.0% and 10.3%, respectively (odds ratio [OR], 9.45; 95% CI, 7.74 to 11.54; p < 0.0001). Similar differences in survival were seen in all major epidemiologic, clinical, and organism subgroups. The decrease in survival with inappropriate initial therapy ranged from 2.3-fold for pneumococcal infection to 17.6-fold with primary bacteremia. After adjustment for acute physiology and chronic health evaluation II score, comorbidities, hospital site, and other potential risk factors, the inappropriateness of initial antimicrobial therapy remained most highly associated with risk of death (OR, 8.99; 95% CI, 6.60 to 12.23).


      Inappropriate initial antimicrobial therapy for septic shock occurs in about 20% of patients and is associated with a fivefold reduction in survival. Efforts to increase the frequency of the appropriateness of initial antimicrobial therapy must be central to efforts to reduce the mortality of patients with septic shock.
      To read this article in full you will need to make a payment


      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Parrillo JE
        Pathogenetic mechanisms of septic shock.
        N Engl J Med. 1993; 328: 1471-1477
        • Brun-Buisson C
        • Doyon F
        • Carlet J
        • et al.
        Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units; French ICU Group for Severe Sepsis.
        JAMA. 1995; 274: 968-974
        • Kumar A
        • Roberts D
        • Wood KE
        • et al.
        Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
        Crit Care Med. 2006; 34: 1589-1596
        • Kollef MH
        • Sherman G
        • Ward S
        • et al.
        Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.
        Chest. 1999; 115: 462-474
        • Parkins MD
        • Sabuda DM
        • Elsayed S
        • et al.
        Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
        J Antimicrob Chemother. 2007; 60: 613-618
        • Tumbarello M
        • Posteraro B
        • Trecarichi EM
        • et al.
        Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia.
        J Clin Microbiol. 2007; 45: 1843-1850
        • Lautenbach E
        • Metlay JP
        • Bilker WB
        • et al.
        Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.
        Clin Infect Dis. 2005; 41: 923-929
        • Lujan M
        • Gallego M
        • Fontanals D
        • et al.
        Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality.
        Crit Care Med. 2004; 32: 625-631
        • McCabe WR
        • Jackson GG
        Gram-negative bacteremia II: clinical, laboratory, and therapeutic observations.
        Arch Intern Med. 1962; 110: 856-864
        • Freid MA
        • Vosti KL
        The importance of underlying disease in patients with gram-negative bacteremia.
        Arch Intern Med. 1968; 121: 418-423
        • Bryant RE
        • Hood AF
        • Hood CE
        • et al.
        Factors affecting mortality of gram-negative rod bacteremia.
        Arch Intern Med. 1971; 127: 120-128
        • Chow JW
        • Fine MJ
        • Shlaes DM
        • et al.
        Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy [comment].
        Ann Intern Med. 1991; 115: 585-590
        • Weinstein MP
        • Murphy JR
        • Reller LB
        • et al.
        The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults: II: clinical observations, with special reference to factors influencing prognosis.
        Rev Infect Dis. 1983; 5: 54-70
        • Vidal F
        • Mensa J
        • Almela M
        • et al.
        Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes.
        Arch Intern Med. 1996; 156: 2121-2126
        • Schiappa DA
        • Hayden MK
        • Matushek MG
        • et al.
        Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.
        J Infect Dis. 1996; 174: 529-536
        • Leibovici L
        • Shraga I
        • Drucker M
        • et al.
        The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.
        J Intern Med. 1998; 244: 379-386
        • Leibovici L
        • Paul M
        • Poznanski O
        • et al.
        Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.
        Antimicrob Agents Chemother. 1997; 41: 1127-1133
        • Leibovici L
        • Drucker M
        • Konigsberger H
        • et al.
        Septic shock in bacteremic patients: risk factors, features, and prognosis.
        Scand J Infect Dis. 1997; 29: 71-75
        • Kreger BE
        • Craven DE
        • McCabe WR
        Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients.
        Am J Med. 1980; 68: 344-355
        • Ibrahim EH
        • Sherman G
        • Ward S
        • et al.
        The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.
        Chest. 2000; 118: 146-155
        • MacArthur RD
        • Miller M
        • Albertson T
        • et al.
        Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.
        Clin Infect Dis. 2004; 38: 284-288
        • Harbarth S
        • Garbino J
        • Pugin J
        • et al.
        Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
        Am J Med. 2003; 115: 529-535
        • Garnacho-Montero J
        • Garcia-Garmendia JL
        • Barrero-Almodovar A
        • et al.
        Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.
        Crit Care Med. 2003; 31: 2742-2751
        • Zaragoza R
        • Artero A
        • Camarena JJ
        • et al.
        The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit.
        Clin Microbiol Infect. 2003; 9: 412-418
        • Fraser A
        • Paul M
        • Almanasreh N
        • et al.
        Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay.
        Am J Med. 2006; 119: 970-976
        • Valles J
        • Rello J
        • Ochagavia A
        • et al.
        Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival.
        Chest. 2003; 123: 1615-1624
        • Kang CI
        • Kim SH
        • Park WB
        • et al.
        Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome.
        Antimicrob Agents Chemother. 2005; 49: 760-766
        • Bone RC
        • Balk R
        • Cerra FB
        • et al.
        Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis: ACCP/SCCM Consensus Conference Committee; American College of Chest Physicians/Society of Critical Care Medicine.
        Chest. 1992; 101: 1644-1655
        • McGeer A
        • Campbell B
        • Emori TG
        • et al.
        Definitions of infection for surveillance in long-term care facilities.
        Am J Infect Control. 1991; 19: 1-7
        • Garner JS
        • Jarvis WR
        • Emori TG
        • et al.
        CDC definitions for nosocomial infections, 1988.
        Am J Infect Control. 1988; 16: 128-140
        • Gilbert DN
        • Moellering Jr, RC
        • Eliopoulos GM
        • et al.
        Clinical approach to initial choice of antimicrobial therapy.
        in: The Sanford guide to antimicrobial therapy. 34th ed. Antimicrobial Therapy, Hyde Park, VT2004: 2-45
        • Knaus WA
        • Draper EA
        APACHE II: a severity of disease classification system.
        Crit Care Med. 1985; 13: 818-829
        • Bernard GR
        • Vincent JL
        • Laterre PF
        Efficacy and safety of recombinant human activated protein C for severe sepsis.
        N Engl J Med. 2001; 344: 699-709
        • Roghmann MC
        Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.
        Arch Intern Med. 2000; 160: 1001-1004
        • Kim SH
        • Park WB
        • Lee CS
        • et al.
        Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores.
        Clin Microbiol Infect. 2006; 12: 13-21
        • Falagas ME
        • Siempos II
        • Bliziotis IA
        • et al.
        Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review.
        Mayo Clin Proc. 2006; 81: 1567-1574
        • Yu VL
        • Chiou CC
        • Feldman C
        • et al.
        An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
        Clin Infect Dis. 2003; 37: 230-237
        • Osih RB
        • McGregor JC
        • Rich SE
        • et al.
        Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.
        Antimicrob Agents Chemother. 2007; 51: 839-844
        • Heyland DK
        • Cook DJ
        • Griffith L
        • et al.
        The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient: the Canadian Critical Trials Group.
        Am J Respir Crit Care Med. 1999; 159: 1249-1256
        • Sotto A
        • Lefrant JY
        • Fabbro-Peray P
        • et al.
        Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis.
        J Antimicrob Chemother. 2002; 50: 569-576
        • Dupont H
        • Montravers P
        • Gauzit R
        • et al.
        Outcome of postoperative pneumonia in the Eole study.
        Intensive Care Med. 2003; 29: 179-188
        • Kang CI
        • Kim SH
        • Park WB
        • et al.
        Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
        Antimicrob Agents Chemother. 2004; 48: 4574-4581
        • Valles J
        • Leon C
        • Alvarez-Lerma F
        Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis: Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC).
        Clin Infect Dis. 1997; 24: 387-395
        • Cavaillon JM
        • Adib-Conquy M
        • Fitting C
        • et al.
        Cytokine cascade in sepsis.
        Scand J Infect Dis. 2003; 35: 535-544
        • Huber TS
        • Gaines GC
        • Welborn III, MB
        • et al.
        Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm.
        Shock. 2000; 13: 425-434
        • Rello J
        • Ricart M
        • Mirelis B
        • et al.
        Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.
        Intensive Care Med. 1994; 20: 94-98